Open an account

CAMP4 Therapeutics

CAMP · NASDAQ

$3.16+$0.02 (+0.64%)TodayMarket closed ·
Prev close $3.14

About CAMP

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company is headquartered in Cambridge, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2024-10-11. The firm is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. The company is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.

Employees
48
Headquarters
Cambridge, Massachusetts
Listed
Oct 11, 2024
Sector
Health Care
Industry
Biotechnology
Website
camp4tx.com

CAMP key statistics

Market cap
198.30M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
277.75K
Volume
89.18K
Open price
$3.18
High today
$3.38
Low today
$3.11
52 Week high
$7.75
52 Week low
$2.88

CAMP4 Therapeutics (CAMP) at a glance

CAMP4 Therapeutics (CAMP) last traded at $3.16, with a market cap of 198.30M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.11 and $3.38. The current price is 1.6% above the day's low and 6.5% below its high.

Volume so far is 89.18K shares, below the average of 277.75K shares a day.

Over the past year CAMP4 Therapeutics has ranged from $2.88 to $7.75, and now sits 6% of the way up that range.

CAMP4 Therapeutics met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.22 per share against an estimate of -$0.2157.

The average analyst price target is $10.20, 222.8% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 7 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $10.20
Low
$6.06
Now
$3.16
High
$15.75

CAMP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 11.4% on average.

  1. Q3 FY24: reported -$24.19 per share against an estimate of -$1.09
  2. Q4 FY24: reported -$2.83 per share against an estimate of -$0.839
  3. Q1 FY25: reported -$0.62 per share against an estimate of -$0.714
  4. Q2 FY25: reported -$0.62 per share against an estimate of -$0.6854
  5. Q3 FY25: reported -$0.55 per share against an estimate of -$0.4879
  6. Q4 FY25: reported -$0.86 per share against an estimate of -$0.3094
  7. Q1 FY26: reported -$0.32 per share against an estimate of -$0.2142
  8. Q2 FY26: reported -$0.22 per share against an estimate of -$0.2157

CAMP news

  • Press releaseGlobe Newswire

    CAMP4 to Participate in Upcoming Investor Conferences

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Vandana Singh

    GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

  • Press releaseGlobe Newswire

    CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Similar companies

Companies in the same industry as CAMP4 Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.